No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CADL Candel Therapeutics
- 8.041
- -0.329-3.93%
Trading Jun 4 12:59 ET
239.28MMarket Cap-6233P/E (TTM)
8.550High7.940Low243.27KVolume8.270Open8.370Pre Close2.00MTurnover1.31%Turnover RatioLossP/E (Static)29.76MShares14.30052wk High40.01P/B149.82MFloat Cap0.66052wk Low--Dividend TTM18.63MShs Float14.780Historical High--Div YieldTTM7.29%Amplitude0.660Historical Low8.223Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
12 Health Care Stocks Moving In Monday's After-Market Session
GainersFibroGen (NASDAQ:FGEN) stock moved upwards by 24.4% to $1.53 during Monday's after-market session. The market value of their outstanding shares is at $152.1 million. Candel Therapeutics (NASDAQ
Express News | Candel Therapeutics Shares up 3.4% After FDA Grants Orphan Drug Tag for Co's Glioma Treatment
Candel Gains FDA Orphan Status for Brain Tumor Candidate
Express News | Market-Moving News for May 30th
Express News | Candel Therapeutics Shares Are Trading Higher After the FDA Granted Orphan Drug Designation to CAN-3110
Express News | Candel Therapeutics Says FDA Granted Orphan Drug Designation To Oncolytic Viral Immunotherapy CAN-3110 For Treatment Of Recurrent High-Grade Glioma
Comments
Work continues
$Rezolute(RZLT.US$
- PB of 2.8
- No debt, 106m cash
$Data Storage(DTST.US$
- Profitable
- P/B 1.15x
- P/S .97x
$Broadwind(BWEN.US$
- Profitable and Undervalued
Gonna add to DTST more. Holding the others for now.
$Candel Therapeutics(CADL.US$
- Unprofitable
- Overbought and bear signals
$Innovative Eyewear(LUCY.US$
- Unprofitable and major cash burn
$XPeng(XPEV.US$
- Unprofitable
- Bearish trend
Gonna sell those positions.
$Rezolute(RZLT.US$
- PB of 2.8
- No debt, 106m cash
$Data Storage(DTST.US$
- Profitable
- P/B 1.15x
- P/S .97x
$Broadwind(BWEN.US$
- Profitable and Undervalued
Gonna add to DTST more. Holding the others for now.
$Candel Therapeutics(CADL.US$
- Unprofitable
- Overbought and bear signals
$Innovative Eyewear(LUCY.US$
- Unprofitable and major cash burn
$XPeng(XPEV.US$
- Unprofitable
- Bearish trend
Gonna sell those positions.
5
2
$Candel Therapeutics(CADL.US$ Reuters· 2 mins ago
FDA Grants Orphan Drug Designation for Can-3110 for the Treatment of Recurrent High-Grade Glioma
FDA Grants Orphan Drug Designation for Can-3110 for the Treatment of Recurrent High-Grade Glioma
3
ColumnsI won't have it!
My daughter will know true freedom.
We like $Candel Therapeutics(CADL.US$
That YTD growth is madness.
Watching $Fitell(FTEL.US$ closely as well
Looking to boost our long game obv.
Added $Vistra Energy(VST.US$
Added $Rezolute(RZLT.US$
Added $Grayscale Bitcoin Trust(GBTC.US$
Added $Data Storage(DTST.US$
These seem to be promising for a 5yr long. I'm gonna be watching and waiting, we will see...
We like $Candel Therapeutics(CADL.US$
That YTD growth is madness.
Watching $Fitell(FTEL.US$ closely as well
Looking to boost our long game obv.
Added $Vistra Energy(VST.US$
Added $Rezolute(RZLT.US$
Added $Grayscale Bitcoin Trust(GBTC.US$
Added $Data Storage(DTST.US$
These seem to be promising for a 5yr long. I'm gonna be watching and waiting, we will see...
4
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg